Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
TERUMO ¥182.5 billion secondary offering
The shares are listed on the Tokyo Stock Exchange
Roche Holdings $2.5 billion notes offering
We advised Roche on the offering comprising three tranches of notes
Inventiva private placement of up to €348 million
The offering includes ordinary shares, pre-funded warrants and warrants
Immatics $150 million follow-on offering
We advised Immatics on the offering of shares
Telemos Capital investment partnership with Helios Global Group
We are advising Telemos Capital on the transaction
Litigation victory for Novo Nordisk on insulin pricing
After six years of litigation, the plaintiffs voluntarily dismissed their case with no recovery of any kind
Labcorp $2 billion senior notes offering
The investment-grade notes are due 2030, 2032 and 2034
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
MBX Biosciences $188 million IPO
The shares are listed on the Nasdaq Global Select Market
Terns Pharmaceuticals $173 million stock and pre-funded warrants offering
The shares are listed on the Nasdaq Global Select Market